If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.

We’ll be back on Monday morning with more fresh content!

The short-term study is believed to be the first to evaluate both interventions combined for people with mental illness.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...